Why the study?
Do live attenuated oral rotavirus vaccines prevent severe acute gastroenteritis in children?
Do live attenuated oral rotavirus vaccines prevent severe acute gastroenteritis in children?
Rotavirus vaccines demonstrate high efficacy against severe gastroenteritis and appear safe, though continued monitoring for intussusception is needed.
Answers are grounded in this paper and cite their sources.
Supports rotavirus vaccination in children; leaves open need for ongoing intussusception surveillance.
Two live attenuated oral rotavirus vaccines were licensed in 2006 for prevention of severe acute gastroenteritis in children: Rotarix (GSK), a human rotavirus vaccine with G1P[8] serotype characteristics and RotaTeq (Merck), a bovine-human reassortant vaccine expressing human G1-4 and P[8] antigens. In prelicensure trials both vaccines showed high efficacy against severe RV gastroenteritis, low reactogenicity and no increased risk for intussusception (IS) (Ruiz-Palacios et al., 2006; Vesikari et al., 2006). Both vaccines have now been distributed in millions of doses. Post-marketing data have not shown any gross signal for IS with either vaccine, but further data and analyses are required for final conclusion on safety of these vaccines.
No takes yet. Share an insight, caveat, or question.
Timo Vesikari (2008) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: